

**Freedom of Information Request**

**Ref: UHB 18-374**

Date 22 June 2018

By Email

Dear Sir/Madam,

Thank you for your request for information under the Freedom of Information Act 2000. The Trusts response is as follows:

**1. In the last 6 months [latest 6 months of data you have available], how many patients with Haemophilia A have been treated with:**

- Advate
- Afstyla
- Elocata
- Emicizumab
- Factor Eight Inhibitor Bypass Activity (FEIBA)
- NovoEight
- Kogenate
- NovoSeven RT
- Nuwiq
- Refacto AF
- Other (Please state)

We are able to obtain this information however we have decided to apply Section 21 of the FOIA as this information is reasonably accessible in the public domain on the following link: <http://www.ukhcdo.org/annual-reports/>. Section 21 of the FOIA provides that we are not obliged to provide the requested information is already reasonably accessible and therefore we are withholding this information at this time.

**2. If possible, could you also supply the above data, but split by severity as follows:**

- Mild (factor level >5%)
- Moderate (factor level 1 – 5%)
- Severe (factor level <1%)

We are able to obtain this information however we have decided to apply Section 21 of the FOIA as this information is reasonably accessible in the public domain on the following link: <http://www.ukhcdo.org/annual-reports/>. Section 21 of the FOIA provides that we are not obliged to provide the requested information is already reasonably accessible and therefore we are withholding this information at this time.

**3. In the last 6 months [latest 6 months of data you have available], how many patients with Haemophilia B have been treated with:**

- **Alprolix**
- **Benefix**
- **Idelvion**
- **Rixubis**
- **Other (please state)**

We are able to obtain this information however we have decided to apply Section 21 of the FOIA as this information is reasonably accessible in the public domain on the following link: <http://www.ukhcdo.org/annual-reports/>. Section 21 of the FOIA provides that we are not obliged to provide the requested information is already reasonably accessible and therefore we are withholding this information at this time.

**4. As with Haemophilia A, if possible please could you split the information by severity?**

- **Mild (factor level >5%)**
- **Moderate (factor level 1 – 5%)**
- **Severe (factor level <1%)**

We are able to obtain this information however we have decided to apply Section 21 of the FOIA as this information is reasonably accessible in the public domain on the following link: <http://www.ukhcdo.org/annual-reports/>. Section 21 of the FOIA provides that we are not obliged to provide the requested information is already reasonably accessible and therefore we are withholding this information at this time.

**5. If you use PK tools, please can you supply the number of patients in the last 6 months using the following:**

- **WAPPS**
- **myPKFIT**
- **Doseme**
- **Optims**

Not applicable

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Trust Secretary  
University Hospitals Bristol NHS Foundation Trust  
Trust Headquarters  
Marlborough Street  
Bristol  
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely,

**FOI Administrator**